

Vanta Bioscience Limited

Regd. Office: 1-20-248, Umajay Complex, Rasoolpura, Secunderabad - 500 003, INDIA. Tel : +91 40 6657 5454, 2790 3226

: +91 40 2790 8708 Fax Website : www.vantabio.com Email : info@vantabio.com CIN No.: L74999TG2016PLC109280

To. The Corporate Relations Department, BSE Ltd.

November 14, 2024

Sub: Outcome of Board Meeting held on 14.11.2024

We wish to inform you that the Board of Directors of the Company in their Board Meeting held today i.e., 14.11.2024, inter alia, considered and approved the following:

- 1. Unaudited Standalone and consolidated financial results for the half year ended 30.09.2024.
- 2. Took note of the Limited Review Report issued by the statutory auditors on the unaudited financial statements for the above said period.

The item w.r.t to conversion of unsecured loan to equity has been deferred to subsequent board meeting owing to want of further information by the Board.

Please find enclosed the standalone and consolidated financial results for the period ended 30.09.2024 along with the Limited Review Report issued by the statutory auditors of the Company.

The meeting commenced at 8.00 P.M. and concluded at 11:15 P.M.

This for your information and dissemination to the public.

for VANTA BIOSCIENCE LIMITED (Scrip Code: 540729 | Scrip ID: VANTABIO)

VENKATA SATHYA MURALI DOKKA **CHIEF FINANCIAL OFFICER**

Tel: 044 6790 1600



Independent Auditor's Limited Review Report on unaudited standalone half yearly and year to date financial results of the Company

To The Board of Directors of Vanta Bioscience Limited

- 1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Vanta Bioscience Limited ("the Company") for the half year ended on 30th September, 2024 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion on the Statement is not modified in respect of the above matters.

FRN:0020203

For MATHESH & RAMANA

CHARTERED ACCOUNTANTS

B.V. RAMANA REDDY M. No. 026967 Partner

Place: Hyderabad Date: 14.11.2024

UDIN: 24026967BKBPEO2375



Independent Auditor's Limited Review Report on unaudited consolidated half yearly and year to date financial results of the Company

To The Board of Directors of Vanta Bioscience Limited

- 1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Vanta Bioscience Limited ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred as "the Group") for the half year ended on 30th September, 2024 ("the statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principle laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the results of the following entities:
 - a. Vanta Bioscience Limited- Parent Company
 - b. Vanta Clinical Research Limited-Subsidiary Company
 - c. Cebis India Limited Associate Company of Subsidiary
- 5. Based on our review conducted and procedure performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

E-mail: mateshca@yahoo.co.in



6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of 1 subsidiary and 1 associate of subsidiary which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total assets of Rs. 3,679.69 Lakhs as at September 30, 2024, total revenues of Rs. 22.96 Lakhs for the half year ended September 30, 2024, total net profit after tax of Rs. (283.64) Lakhs and cash flows of Rs. 0.34 Lakhs for the period from 1stApril, 2024 to 30th September, 2024, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For MATHESH & RAMANA

CHARTERED ACCOUNTANTS

B.V. RAMANA REDDY M. No. 026967 Partner

Place: Hyderabad Date: 14.11.2024

UDIN: 24026967BKBPEP9223

NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003 CIN L74999TG2016PLC109280

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2024

(Rupees. In Lacs)

		STANDALONE				
Sr.No	Particualrs	HALF YEAR ENDED			YEAR ENDED	
		30.09.2024	30.09.2023	31.03.2024	31.03.2024	
		(Un Audited)	(Un Audited)	(Audited)	(Audited)	
1	Income					
	Revenue from Operation	80.09	523.24	332.55	855.79	
	Other Income	0.00	0.00	4.77	4.77	
	Total Revenue	80.09	523.24	337.32	860.56	
2	Evnoncos					
	Expenses a) Cost of material Consumed	18.13	49.81	14.94	64.75	
	b) Changes In Inventories: Work in progress	(151.69)	0.00	(38.18)		
	b) Employee Benfit Expenses	109.62	141.79	125.81		
	c) Financial Cost	72.39	130.73	111.50	242.23	
	d) Depreciation and amortization Exp	61.49	62.61	60.99	123.60	
	e) other expenses	102.47	123.30	73.09	196.39	
	Total Expenses	212.41	508.24	348.15	856.39	
	Profit/(Loss) from ordinary activities before					
3	Exceptional Items (1-2)	(132.32)	15.00	(10.83)	4.17	
4	Exceptional Items Income /(Expenses)	0.00	0.00	0.00	0.00	
, 5	Profit/(Loss) from oridnary activities before tax (3+4)	(132.32)	15.00	(10.83)	4.17	
6	Minority Interest	0.00	0.00	0.00	0.00	
7	Net Profit/(Loss) after Minority Interest (5-6)	(132.32)	15.00	(10.83)	4.17	
8	Tax Expenses					
	a) Current Tax	0.00	(3.62)	4.27	0.65	
	b) MAT Credit Availed	0.00	0.00	(0.65)	(0.65)	
	c) Deferred Tax	2.98	1.07	(0.13)	0.94	
9	Net Profit/(Loss) from ordinary activities after tax (7+8)	(129.34)	12.45	(7.34)	5.11	
10	Other Comprehensive Income / (expenses) for the year, net of tax	0.00	0.00	0.00	0.00	
11	Total Comprehensive Income/(Loss) Net of Tax (9+10)	(129.34)	12.45	(7.34)	5.11	
12	Paid up Equity share capital (face value of Rs.10/-)	631.20 ⁻	631.20	631.20	631.20	
13	Reserve excluding Revaluation reserve					
14	Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised)					
	a) Basic (Rs.)	-2.05	0.20	-0.12	0.08	
	b) Diluted (Rs.)	-2.05	0.20	-0.12	0.08	
	Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised)	-2.03	0.20	-0.12	0.00	
	a) Basic (Rs.)	-2.05	0.20	-0.12	0.08	
	b) Diluted (Rs.)	-2.05	0.20	-0.12		

For and on behalf of Board of Directors

Vanta Bioscience Limited

Place: Hyderabad Date: 14.11.2024 Dopesh Raja Mulakata Managing Director

DIN:01176660

NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003 CIN L74999TG2016PLC109280

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2024

(Rupees. In Lacs)

No. Particularis 30.09.2024 30.09.2023 31.03.2024 31.03.202 (Un Audited) (Audited) (Particualrs	CONSOLIDATED				
Income Revenue from Operation 103.05 617.59 354.70 972.2	Sr.No		HALF YEAR ENDED			YEAR ENDED	
Income Revenue from Operation 103.05 617.59 354.70 972.2		,	30.09.2024	30.09.2023	31.03.2024	31.03.2024	
Revenue from Operation			(Un Audited)	(Un Audited)	(Audited)	(Audited)	
Other Income 3.98 2.97 7.67 10.6 Total Revenue 107.03 620.56 362.37 982.9 Expenses 2	1	Income					
Total Revenue		Revenue from Operation	103.05	617.59	354.70	972.29	
2 Expenses a) Cost of material Consumed b) Changes In Inventories: Work in progress (151.69) 0.00 (38.18) (38.18) b) Employee Benfit Expenses 131.23 169.28 210.13 379.4 c) Financial Cost 214.44 284.97 289.93 574.9 d) Depreciation and amortization Exp e) other expenses 139.80 163.57 226.01 389.5 Total Expenses 70 Total Expenses 139.80 163.57 226.01 389.5 Profit/(Loss) from ordinary activities before Exceptional Items (1-2) Exceptional Items Income /(Expenses) Minority Interest Common Minor		Other Income	3.98	2.97	7.67	10.64	
a) Cost of material Consumed b) Changes In Inventories: Work in progress c) Changes In Inventories: Work in progress c) Changes In Inventories: Work in progress c) Financial Cost c) Employee Benfit Expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Cost Cost Cost Cost Cost Cost Cost Cost		Total Revenue	107.03	620.56	362.37	982.92	
a) Cost of material Consumed b) Changes In Inventories: Work in progress c) Changes In Inventories: Work in progress c) Changes In Inventories: Work in progress c) Financial Cost c) Employee Benfit Expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Depreciation and amortization Exp e) other expenses c) Chianacial Cost d) Cost Cost Cost Cost Cost Cost Cost Cost	2	Evmonsos					
b) Changes In Inventories : Work in progress b) Employee Benfit Expenses c) Financial Cost c) Employee Benfit Expenses c) Financial Cost c) Financial Cost d) Depreciation and amortization Exp e) other expenses for a state of the expenses for the expenses for a state of the expenses of the expense of the state of the expenses of the expense of the expenses of the expense of the expense of the expense of the state of the expense of the expen	2	-	21 00	79 20	21 00	110 10	
b) Employee Benfit Expenses c) Financial Cost d) Perpeciation and amortization Exp e) other expenses e) other expenses froital Expenses Total Expenses Frofit/(Loss) from ordinary activities before Exceptional Items (1-2) Exceptional Items Income /(Expenses) Total Expenses Profit/(Loss) from ordinary activities before Exceptional Items Income /(Expenses) Net Profit/(Loss) after Minority Interest (5-6) Exact Expenses a) Current Tax b) MAT Credit Availed c) C) Deferred Tax A.6.2 C) Deferred Tax A.6.3 C) Deferred Tax A.6.4 C) Deferred Tax A.6.5 C) Deferred Tax A.6.6 C) Deferred Tax A.6.6 C) Deferred Tax A.6.7 C) Deferred Tax A.6.7 C) Deferred Tax A.6.8 C) Deferred Tax A.6.9 C) Deferred Tax A.6.0 C) Deferred Tax A.6.0 C) Deferred Tax A.6.1 C) Deferred Tax A.6.2 C) Deferred Tax A.6.3 C) Deferred Tax A.6.4 C) Deferred Tax A.6.5 C) Deferred Tax A.6.6 C) Deferred Tax A.6.7 C) Deferred Tax A.6.7 C) Deferred Tax A.6.7 C) Deferred Tax A.6.8 C) Deferred Tax A.6.9 C) Deferred Tax A.6.0 C) Deferred Tax A.6.0 C) Deferred Tax A.6.0 C) Deferred Tax A.6.1 C) Deferred Tax A.6.2 C) Deferred Tax A.6.3 C) Deferred Tax A.6.4 C) Deferred Tax A.6.5 C) Deferred Tax A.6.6 C) Deferred Tax A.6.7 C) Deferred Tax A.6.7 C) Deferred Tax A.6.8 C) Deferred Tax A.6.9 C) Deferred Tax A.6.9 C) Deferred Tax A.6.9 C) Deferred Tax A.6.1 C) Deferred Tax A.6.2 C) Deferred Tax A.6.2 C) Deferred Tax A.6.3 C) Deferred Tax A.6.5 C) Deferred Tax A.6.6 C) Deferred Tax A.6.7 C) Deferred Tax A.6.8 C) Deferred Tax A.6.8 C) Deferred Tax A.6.9 C		*					
c) Financial Cost d) Depreciation and amortization Exp e) other expenses 139.80 Total Expenses 524.62 850.59 1014.99 1865.5 3 Profit/(Loss) from ordinary activities before Exceptional Items (1-2) Exceptional Items (1-2) Exceptional Items Income /(Expenses) 6 Minority Interest Correct Tax Diaz Expenses a) Current Tax b) MAT Credit Availed c) Deferred Tax C) Deferred Tax C) Deferred Tax C) Deferred Tax C) Cher Comprehensive Income / (expenses) for the year, net of tax Total Comprehensive Income / (expenses) for the year, net of tax C) Paid up Equity share capital (face value of Rs.10/-) B) Casco (Rs.) B) Casco (Not Anualised) a) Basic (Rs.) B) Dilluted (Rs.) E-2.82 B-3.68 B-3.0 Each (Not Anualised) a) Basic (Rs.) B-3.28 B-3.28 B-3.88 B-3.28 B-3.68 B-3.28 B-3.68 B-3.28 B-3.68 B-3.28 B-3.88 B-3.28 B-3.68 B-3.68 B-3.28 B-3.68 B-3.28 B-3.68 B-3.68 B-3.28 B-3.68 B-3.28 B-3.68 B-3.28 B-3.68 B-3.28 B-3.68 B-3.28 B-3.68 B-3.28 B-3.68							
d) Depreciation and amortization Exp e) other expenses 139.80 163.57 226.01 389.5 Total Expenses 524.62 850.59 1014.99 1865.5 3 Profit/(Loss) from ordinary activities before Exceptional Items (1-2) 4 Exceptional Items Income /(Expenses) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.			/				
e) other expenses Total Expenses Forfit/(Loss) from ordinary activities before Exceptional Items (1-2) Exceptional Items Income /(Expenses) Ounce (230.03) Exceptional Items Income /(Expenses) Profit/(Loss) from oridnary activities before tax (3+4) Exceptional Items Income /(Expenses) Nounce (200.09) Exceptional Items Income /(Expenses) Exceptional Items Income /(Expenses) Exceptional Items Income /(Expenses) Exceptional Items Income /(Expenses) Double (230.03) Exceptional Items Income /(Expenses) Exceptional Items Income /(Expenses) Exceptional Items Income /(Expenses) Exceptional Items Income /(Expenses) Exceptional Items (1-2) Exceptional Items (1-2) Exceptional Items (1-2) Exceptional Items (1-2) (417.59) Exceptional Items (1-2) (230.03) Exceptional Items (652.63) Exceptional Items Income /(Expenses) Exceptional Items (1-2) (200.00) Exceptional Items (1-2) (210.00) Exceptional Items (1-2) (220.00) (230.00) Exceptional Items (1-2) (245.90) Exceptional Items (1-2) (245.90) Exceptional Items (1-2) (247.90) Exceptional Items (1-2) (250.63) Exceptional Items (1-2) (250.63) Exceptional Items (1-2) (250.63) Exceptional Items (1-2) (250.63) Exceptional Items (1-2) Exceptional Items (1-10) Exceptional Items (1-2) Exceptional Items (1-10) Exce		· ·				1	
Total Expenses Frofit/(Loss) from ordinary activities before Exceptional Items (1-2) Exceptional Items (1-2) Exceptional Items (1-2) Exceptional Items (1-2) Exceptional Items Income /(Expenses) 0.00 0.05 0.						I .	
Profit/(Loss) from ordinary activities before Exceptional Items (1-2)							
Exceptional Items (1-2) (417.59) (230.03) (652.63) (882.64)			524.62	850.59	1014.99	1865.58	
4 Exceptional Items Income /(Expenses) 0.00 0.00 0.00 0.00 5 Profit/(Loss) from oridinary activities before tax (3+4) (417.59) (230.03) (652.63) (882.66 6 Minority Interest (206.09) (174.12) (454.93) (629.05 7 Net Profit/(Loss) after Minority Interest (5-6) (211.50) (55.91) (197.70) (253.63 8 Tax Expenses	3		(417.59)	(230.03)	(652.63)	(882.66)	
5 Profit/(Loss) from oridnary activities before tax (3+4) (417.59) (230.03) (652.63) (882.66) 6 Minority Interest (206.09) (174.12) (454.93) (629.05) 7 Net Profit/(Loss) after Minority Interest (5-6) (211.50) (55.91) (197.70) (253.61) 8 Tax Expenses	4		0.00	0.00	0.00	0.00	
Net Profit/(Loss) after Minority Interest (5-6) (211.50) (55.91) (197.70) (253.61)	5		(417.59)	(230.03)			
8 Tax Expenses	6	Minority Interest	(206.09)	(174.12)	(454.93)	(629.05)	
a) Current Tax b) MAT Credit Availed c) Deferred Tax 4.62 5.89 16.13 22.02 9 Net Profit/(Loss) from ordinary activities after tax (7+8) 10 Other Comprehensive Income / (expenses) for the year, net of tax 11 Total Comprehensive Income/(Loss) Net of Tax (9+10) 12 Paid up Equity share capital (face value of Rs.10/-) 13 Reserve excluding Revaluation reserve Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) 5.0 Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.66 -3.20 -3.28 -0.85 -2.82 -3.66 -3.28 -3.28 -3.66 -3.66	7	Net Profit/(Loss) after Minority Interest (5-6)	(211.50)	(55.91)	(197.70)	(253.61)	
b) MAT Credit Availed c) Deferred Tax 4.62 5.89 16.13 22.02 9 Net Profit/(Loss) from ordinary activities after tax (7+8) 10 Other Comprehensive Income / (expenses) for the year, net of tax 11 Total Comprehensive Income/(Loss) Net of Tax (9+10) 12 Paid up Equity share capital (face value of Rs.10/-) 13 Reserve excluding Revaluation reserve Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) 14 b) Diluted (Rs.) Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6 -3.28 -0.85 -2.82 -3.6 -3.6 -3.28 -0.85 -2.82 -3.6 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.6 -3.28 -3.6 -3.28 -3.6 -3.28 -3.6 -3.6 -3.28 -3.6 -3.6 -3.28 -3.6 -3.6 -3.28 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6	8	Tax Expenses					
c) Deferred Tax		a) Current Tax	0.00	(3.62)	4.27	0.65	
c) Deferred Tax 4.62 5.89 16.13 22.02 Net Profit/(Loss) from ordinary activities after tax (7+8) (206.88) (53.64) (177.95) (231.59) Other Comprehensive Income / (expenses) for the year, net of tax Total Comprehensive Income/(Loss) Net of Tax (9+10) (231.59) Paid up Equity share capital (face value of Rs.10/-) 631.20 631.20 631.20 631.20 Reserve excluding Revaluation reserve Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6 Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6 Basic (Rs.) -3.28 -0.85 -2.82 -3.6 Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6		b) MAT Credit Availed	0.00	0.00	(0.65)	(0.65)	
9 Net Profit/(Loss) from ordinary activities after tax (7+8)		c) Deferred Tax	4.62	5.89		22.02	
Total Comprehensive Income/(Loss) Net of Tax (9+10) (231.59) Paid up Equity share capital (face value of Rs.10/-) 631.20 631.20 631.20 631.20 Reserve excluding Revaluation reserve Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6 Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) -3.28 -0.85 -2.82 -3.6 Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) -3.28 -0.85 -2.82 -3.6	9		(206.88)	(53.64)	(177.95)		
11	10		0.00	0.00	0.00	0.00	
Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) b) Diluted (Rs.) Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6 Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6	11		(206.88)	(53.64)	(177.95)	(231.59)	
Earning per share of (before extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) b) Diluted (Rs.) Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6 Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6	12	Paid up Equity share capital (face value of Rs.10/-)	631.20	631.20	631.20	631.20	
Rs.10 Each (Not Anualised) a) Basic (Rs.) b) Diluted (Rs.) Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6 -3.6 -3.28 -0.85 -2.82 -3.6 -3.6 -3.28 -3.6	13	Reserve excluding Revaluation reserve					
b) Diluted (Rs.) Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6	14						
b) Diluted (Rs.) Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6		a) Basic (Rs.)	-3 28	-O 25	_2 22	-3 67	
Earning per share of after extra ordinary items) Rs.10 Each (Not Anualised) a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6						1	
a) Basic (Rs.) -3.28 -0.85 -2.82 -3.6		Earning per share of after extra ordinary items)	-5.20	-0.83	-2.02	-5.07	
			2 20	0.05	2 02	2 67	
		b) Diluted (Rs.)	-3.28	-0.85	-2.82	1	

For and on behalf of Board of Directors

Vanta Bioscience Limited

Dopesh Raja Mulakala Managing Director

DIN:011766600

Place: Hyderabad Date: 14.11.2024

NO.02/G/308/G NO.3/FF/SF/1-20-248 UMAJAY COMPLEX RASOOLPURA SECUNDERABAD - 500003 CIN L74999TG2016PLC109280

STATEMENT OF ASSSETS & LIABILITIES AS ON 30th SEPTEMBER 2024

A Equity and Liabilities Equity share capital 631.20 631.		STATEMENT OF ASSSETS & LIABILITIE				IID ATES
A Equity and Liabilities CQUITY a) Equity share capital 631.20			STANDALONE CONSOLIDATED			
A Equity and Liabilities 1 EQUITY a) Equity share capital b) Reserve & Surplus c) Non Controlling/Minority Interest 0.00 0.00 4.26.65 - 222.55 Sub total Equity 1 II. Share Application Money pending allotment LIABILITIES Non Current Liabilities a) Financial Liabilities i) Borrowings 1 1879.22 1 III. Share Application Money pending allotment LIABILITIES Non Current Liabilities a) Financial Liabilities i) Borrowings 1 1879.22 1 III. Share Application Money pending allotment LIABILITIES LIABILITIES Non Current Liabilities a) Financial Liabilities i) Borrowings 1 1879.22 1 III. 20 5 211.83 4 880.14 6 9.91 7 47.55 d) Other Non Current Liabilities 1 1956.47 1 1891.44 5 281.74 4 9554.65 Current Liabilities a) Financial Liabilities b) Borrowings a) Financial Liabilities a) Financial Liabilities b) Borrowings a) Financial Liabilities a) Financial Liabilities b) Borrowings a) Financial Liabilities b) Borrowings a) Financial Liabilities b) Other Current Liabilities a) Financial Liabilities b) Other Current Liabilities a) Financial Liabilities b) Other Current Liabilities c) Financial Assets c) Provisions c) Oo	Sr.No.	Particualrs				31.03.2023
1 EQUITY			Un Audited	Audited	Un Audited	Audited
a) Equity share capital b) Reserve & Surprius (2) Non Contortiling/Minority Interest (2) Non Contortiling/Minority Interest (3) Non Contortiling/Minority (3		Equity and Liabilities				
b) Reserve & Surplus c) Non Controlling/Minority Interest O.00 0.00 4.28.65 -22.2.66 Sub total Equity 1849.94 1979.28 884.35 1297.32 II. Share Application Money pending allotment LIABILITIES Non Current Liabilities a) Financial Liabilities i) Borrowings b) Provisions O.00 C) Defered tax Liabilities d) Other Non Current Liabilities a) Financial Liabilities a) Financial Liabilities a) Financial Liabilities d) Other Non Current Liabilities a) Financial Liabilities b) Frovisions C) O.00 C) O.00 C) O.00 C) O.00 Sub Total Non Current Liabilities b) Frovisions C) O.00	1					
c) Non Contorling/Minority Interest Sub total Equity II. Share Application Money pending allotment LIABILITIES Non Current Liabilities i) Borrowings i) Provisions () Defered tax Liabilities a) Financial Liabilities i) Borrowings i) Provisions () O.00 () Defered tax Liabilities a) Financial Liabilities i) Borrowings i) Provisions () O.00 (a) Equity share capital	631.20	631.20	631.20	631.20
Sub total Equity		b) Reserve & Surplus	1218.74	1348.08	681.80	888.69
List		c) Non Contorlling/Minority Interest	0.00	0.00	-428.65	-222.56
LIABILITIES Non Current Liabilities a) Financial Liabilities i) Borrowings 1879.22 1811.20 5211.83 4880.14 c) Defered tax Liabilities 77.25 80.24 69.91 74.55 77.2		Sub total Equity	1849.94	1979.28	884.35	1297.33
LIABILITIES Non Current Liabilities a) Financial Liabilities i) Borrowings 1879.22 1811.20 5211.83 4880.14 c) Defered tax Liabilities 77.25 80.24 69.91 74.55 77.2						
Non Current Liabilities 3 Financial Liabilities 3 Financial Liabilities 3 Financial Liabilities 3 Financial Liabilities 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 72.81 74.55 72.81 74.55 72.81 74.55 72.81 74.55 74	2	II. Share Application Money pending allotment			50.00	
Non Current Liabilities 3 Financial Liabilities 3 Financial Liabilities 3 Financial Liabilities 3 Financial Liabilities 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 69.91 74.55 77.25 80.24 72.81 74.55 72.81 74.55 72.81 74.55 72.81 74.55 74						
a) Financial Liabilities i) Borrowings b) Provisions c) Defered tax Liabilities d) O.00 c) O.00 c) Defered tax Liabilities d) O.00 c)		LIABILITIES				
i) Borrowings b) Provisions 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	2	Non Current Liabilities				
b) Provisions c) Defered tax Liabilities d) Other Non Current Liabilities 3) Current Liabilities a) Final Defered tax Liabilities 3) Final Defered tax Liabilities 3) Final Defered tax Liabilities a) Final Defered tax Liabilities b) Borrowings ii) Trade Payables (a) Total Outstanding dues of Micro Enterprises and Small Enterprises (b) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises b) Other Current Liabilities b) Other Current Liabilities b) Other Current Liabilities c) Provisions c) Dougle Defered tax Liabilities c) Defered Defered tax Liabilities c) Defered Defered tax Liabilities c) Defered tax Liabilities c) Defered Defered Defered Defered D		a) Financial Liabilities				
c) Defered tax Liabilities 77.25 80.24 69.91 74.55 d) Other Non Current Liabilities 1956.47 1891.44 5281.74 4954.65 Current Liabilities 3 Financial Liabilities 4 75.25 5 5 5 5 5 5 (b) Total Outstanding dues of Micro 5 Financial Liabilities 4 7 7 7 7 7 7 7 7 7		i) Borrowings	1879.22	1811.20	5211.83	4880.14
d) Other Non Current Liabilities		b) Provisions	0.00	0.00	0.00	0.00
d) Other Non Current Liabilities			77.25	80.24	69.91	74.53
Sub Total - Non Current Liabilities 1956.47 1891.44 5281.74 4954.65 a) Financial Liabilities 1) Borrowings 867.28 726.81 1370.24 1215.25 ii) Trade Payables (a) Total Outstanding dues of Micro Enterprises and Small Enterprises (b) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises 176.44 222.24 522.96 556.85 b) Other Current Liabilities 427.57 471.22 455.23 515.57 c) Provisions 0.00 0.00 0.00 0.00 0.00 d) Current tax Liabilities 0.00 0.00 0.00 0.00 0.00 Sub Total - Non Current Liabilities 1471.29 1420.27 2348.43 2287.65 Total Equity and Liabilities 5277.70 5290.99 8564.52 8539.66 B ASSETS 3 Non Current Assets a) Property, Plant and Equipment 1151.26 1212.75 2630.83 2840.66 b) Capital Work in Progress 0.00 0.00 0.00 0.00 c) Other Intangible assets under development 0.00 0.00 1457.15 1253.47 d) Other Intangible assets under development 0.00 0.00 0.00 0.00 ii) Financial Assets 0.00 0.00 0.00 0.00 iii) Other Financial Assets 0.94 0.94 155.64 154.88 Sub Total Non-CurrentAssets 0.94 0.94 155.64 154.88 Sub Total Non-CurrentAssets 0.00 0.00 0.00 0.00 iii) Trade Receivable 176.57 233.72 244.46 314.01 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.01 iii) Jank, Cash and Cash equivalents 14.14 14.14 16.41 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 iii) Bank, Cash and Cash equivalents				0.00		0.00
Current Liabilities a) Financial Liabilities		,				
a) Financial Liabilities i) Borrowings ii) Trade Payables (a) Total Outstanding dues of Micro Enterprises and Small Enterprises (b) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises b) Other Current Liabilities c) Provisions d) Current tax Liabilities d) Current tax Liabilities 1471.29 Total Equity and Liabilities 15277.70 Total Equity and Liabilities 15274.70 Total Equity an	3		2556117	2002111	5202171	133 1107
i) Borrowings ii) Trade Payables (a) Total Outstanding dues of Micro Enterprises and Small Enterprises (b) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises b) Other Current Liabilities 427.57 471.22 455.23 515.55. c) Provisions 0.00 0.00 0.00 0.00 0.00 Gurrent tax Liabilities(net) 0.00 0.00 0.00 0.00 Sub Total -Non Current Liabilities 1471.29 1420.27 2348.43 2287.64 Total Equity and Liabilities 5277.70 5290.99 8564.52 8539.64 ASSETS Non Current Assets a) Property, Plant and Equipment b) Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 c) Other Intangible assets under development 0.00 0.00 0.00 0.00 0.00 f) Financial Assets i) Investments in Subsidary ii) Loans iii) Other Financial Assets 5ub Total Non-Current assets 3 Property Assets i) Investments ii) Trade Receivable iii) Bank, Cash and Cash equivalents 176.44 222.24 522.96 556.84 1212.75 47.12 455.23 515.55 122.76 471.22 455.23 515.55 123.77 5290.99 8564.52 8539.64 1227.77 5290.99 8564.52 8539.64 1228.78 527.70 5290.99 8564.52 8539.64 1228.78 527.70 5290.99 8564.52 8539.64 1228.78 527.70 5290.99 8564.52 8539.64 1228.78 527.70 5290.99 8564.52 8539.64 1228.78 5290.99 8564.52 8539.64 1228.78 5290.99 8564.52 8539.64 1228.78 5290.99 8564.52 8539.64 1228.78 5290.99 8564.52 8539.64 1228.78 5290.99 8564.52 8539.64 1228.78 5290.99 8564.52 8539.64 1228.78 5290.99 8564.52 8539.64 1228.78 64.78						
ii) Trade Payables			867.28	726 81	1270 24	1215 21
(a) Total Outstanding dues of Micro Enterprises and Small Enterprises (b) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises b) Other Current Liabilities c) Provisions d) Current tax Liabilities (net) Sub Total -Non Current Liabilities 1471.29 1420.27 2348.43 2287.66 Total Equity and Liabilities 1471.29 1420.27 2348.43 2287.66 Total Equity and Liabilities 5277.70 5290.99 8564.52 8539.66 B ASSETS 1 Non Current Assets a) Property, Plant and Equipment b) Capital Work in Progress c) 0.00 c) Other Intangible assets d) Other Intangible assets under development e) Investment in associates and joint ventres 0.00 0.00 0.00 0.00 f) Financial Assets 0.00 0.00 0.00 ii) Loans iii) Other Financial Assets 0.00			807.28	/20.81	15/0.24	1215.21
Enterprises and Small Enterprises						
(b) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises b) Other Current Liabilities c) Provisions d) Current tax Liabilities(net) Sub Total Non Current Liabilities 1471.29 1420.27 2348.43 2287.66 Total Equity and Liabilities 5277.70 5290.99 8564.52 8539.66 B ASSETS 1 Non Current Assets a) Property, Plant and Equipment b) Capital Work in Progress c) Other Intangible assets under development c) Other Intangible assets under development e) Investment in associates and joint ventres 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.						
than Micro Enterprises and Small Enterprises b) Other Current Liabilities		Enterprises and Small Enterprises				
than Micro Enterprises and Small Enterprises b) Other Current Liabilities		(b) Total Outstanding dues of Creditors other	176 14	222.24	F22.06	FF6.00
b) Other Current Liabilities		than Micro Enterprises and Small Enterprises	1/6.44	222.24	522.96	556.88
c) Provisions d) Current tax Liabilities(net) D.00 D.00 D.00 D.00 D.00 D.00 D.00 D.0			407.57	474.00	455.00	
d) Current tax Liabilities (net)						
Sub Total -Non Current Liabilities 1471.29 1420.27 2348.43 2287.66 Total Equity and Liabilities 5277.70 5290.99 8564.52 8539.66 ASSETS						
Total Equity and Liabilities 5277.70 5290.99 8564.52 8539.66	-					
ASSETS Non Current Assets a) Property, Plant and Equipment 1151.26 1212.75 2630.83 2840.60 b) Capital Work in Progress 0.00						
Non Current Assets			5277.70	5290.99	8564.52	8539.66
a) Property, Plant and Equipment b) Capital Work in Progress 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0						
b) Capital Work in Progress	1					
c) Other Intangible assets d) Other Intangible assets d) Other Intangible assets under development e) Investment in associates and joint ventres e) Investment in associates and joint ventres f) 0.00 f) Financial Assets 0.00 i) Investments in Subsidary 300.00 ii) Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.						
d) Other Intangible assets under development e) Investment in associates and joint ventres e) Investment in associates and joint ventres f) Financial Assets f) Financ		, ,				
e) Investment in associates and joint ventres			2574.70	2574.70	2574.70	
f) Financial Assets i) Investments in Subsidary ii) Loans iii) Other Financial Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.			0.00	0.00	1457.15	1253.42
i) Investments in Subsidary 300.00 300.00 0.00 0.00 ii) Loans 0.00 0.00 0.00 0.00 iii) Other Financial Assets 0.00 0.00 0.00 0.00 g) Defered tax assets (net) 0.00 0.00 0.00 0.00 h) Other non current assets 0.94 0.94 155.64 154.86 Sub Total Non-CurrentAssets 4026.90 4088.39 6818.32 6823.58 2 Current Assets 897.82 748.48 901.84 752.09 b) Financial Assets 0.00 0.00 0.00 0.00 ii) Investments 0.00 0.00 0.00 0.00 iii) Bank, Cash and Cash equivalents 176.57 233.72 244.46 314.09 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.00 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) O		e) Investment in associates and joint ventres	0.00	0.00	0.00	0.00
ii) Loans		f) Financial Assets	0.00	0.00	0.00	0.00
iii) Other Financial Assets 0.00 0.00 0.00 0.00 g) Defered tax assets (net) 0.00 0.00 0.00 0.00 h) Other non current assets 0.94 0.94 155.64 154.86 Sub Total Non-CurrentAssets 4026.90 4088.39 6818.32 6823.56 Current Assets 897.82 748.48 901.84 752.05 b) Financial Assets 0.00 0.00 0.00 0.00 ii) Investments 0.00 0.00 0.00 0.00 iii) Trade Receivable 176.57 233.72 244.46 314.05 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08		i) Investments in Subsidary	300.00	300.00	0.00	0.00
g) Defered tax assets (net) 0.00 0.00 0.00 0.00 0.00 h) Other non current assets 0.94 0.94 155.64 154.86 Sub Total Non-CurrentAssets 4026.90 4088.39 6818.32 6823.56 Current Assets		ii) Loans	0.00	0.00	0.00	0.00
h) Other non current assets 0.94 0.94 155.64 154.86 Sub Total Non-CurrentAssets 4026.90 4088.39 6818.32 6823.56 Current Assets a) Inventories 897.82 748.48 901.84 752.05 b) Financial Assets i) Investments 0.00 0.00 0.00 0.00 ii) Trade Receivable 176.57 233.72 244.46 314.05 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.06		iii) Other Financial Assets	0.00	0.00	0.00	0.00
h) Other non current assets 0.94 0.94 155.64 154.86 Sub Total Non-CurrentAssets 4026.90 4088.39 6818.32 6823.56 Current Assets a) Inventories 897.82 748.48 901.84 752.05 b) Financial Assets i) Investments 0.00 0.00 0.00 0.00 ii) Trade Receivable 176.57 233.72 244.46 314.05 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.06		g) Defered tax assets (net)	0.00	0.00	0.00	0.00
Sub Total Non-CurrentAssets 4026.90 4088.39 6818.32 6823.58 Current Assets 897.82 748.48 901.84 752.09 b) Financial Assets 0.00 0.00 0.00 0.00 ii) Investments 0.00 0.00 0.00 0.00 iii) Trade Receivable 176.57 233.72 244.46 314.09 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.00 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08		h) Other non current assets	0.94	0.94	155.64	154.86
2 Current Assets a) Inventories 897.82 748.48 901.84 752.05 b) Financial Assets 0.00 0.00 0.00 0.00 ii) Trade Receivable 176.57 233.72 244.46 314.05 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08						
a) Inventories 897.82 748.48 901.84 752.05 b) Financial Assets i) Investments 0.00 0.00 0.00 0.00 ii) Trade Receivable 176.57 233.72 244.46 314.05 iii) Bank, Cash and Cash equivalents 14.14 16.41 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08	2	Current Assets				
b) Financial Assets i) Investments 0.00 0.00 0.00 0.00 ii) Trade Receivable 176.57 233.72 244.46 314.09 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.00 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.			897.82	748.48	901.84	752.05
i) Investments 0.00 0.00 0.00 0.00 ii) Trade Receivable 176.57 233.72 244.46 314.09 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08		· ·				
ii) Trade Receivable 176.57 233.72 244.46 314.09 iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08			0.00	0.00	0.00	0.00
iii) Bank, Cash and Cash equivalents 14.14 14.14 16.41 16.06 iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08						
iv) Loans & Advances 108.82 152.88 526.77 577.44 iv) Othe Financial Assets 0.00 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08						
iv) Othe Financial Assets 0.00 0.00 0.00 0.00 c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08						
c) Current Tax Assets (net) 0.00 0.00 0.00 0.00 d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08						
d) Other Current Assets 53.45 53.38 56.72 56.44 Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08						
Sub Total Current Assets 1250.80 1202.60 1746.20 1716.08						
		-				
Total Assets ' 5277.70 5290.99 8564.52 8539.60						
For and on hehalf of Board of Directors		Total Assets				8539.66

For and on behalf of Board of Directors

Place: Hyderabad Date: 14.11.2024 Dopesh Raja Mulakata Managing Director DIN:01176660

Cash Flow statement for the period ended 30th SEPTEMBER, 2024

(Rupees in Lacs) STANDALONE CONSOLIDATED For the Half For the Year For the Half For the Year Particulars Year ended ended ended Year ended 30.09.2024 31.03.2024 30.09.2024 31.03.2024 A. Cash Flow from Operating Activities Profit before exceptional, Extraordinary items and Tax (417.59) (132.32)4.17 (882.66) Adjustment for: Depreciation 61.48 123.59 168.85 449.68 Finance Charges 72.39 242.23 214.44 574.89 Profit on Sale of Fixed Assets (4.25)(4.25)133.87 361.57 383.29 1,020.33 Operating profit Before Working Capital Changes 1.55 365.74 (34.30)137.67 Adjustment for: (Increase) /Decrease in Inventories -149.34 -32.72 (149.78) (36.30)(Increase) /Decrease in Trade receivables 57.16 -41.39 69.63 (118.20)Increase / (Decrease) in Current Liabilities -89.45 160.78 (94.26)307.19 (Increase) /Decrease Loans & Advances 43,99 2.45 50.66 (39.45)(Increase) /Decrease Current Assets (1.07)17.49 (Increase) /Decrease in Current Investment 0.00 Sub total (137.64)89.12 (124.82) 130.73 Cash Generated from operations (136.09) 454.86 -159.12 268.40 Net Cash Flow from Operating Activities (136.09)454.86 (159.12) 268.40 B: Cash Flow from Investing Activities Purchase of Fixed Assets (0.65)(162.82)(340.47)Capital Work In progress Capital Work In progress-R&D (175.17)proceeds from sale of Fixed Assets 9.15 9.15 Investment in Subsidiaries Purchase of other Non current Investments Net Cash Flow from Investing Activites (331.32)(166.66)(162.82)C: Cash Flow from Financing Activites Increase / (Decrease) in Unsecured Loan 565.43 771.93 Increase /(Decrease) in Working capital 140.47 234.99 249.49 110.52 Increase /(Decrease) in Term Loan 68.01 -272.83(328.21)(503.24)Increase / (Decrease) in Long Term Borrowings Increase / (Decrease) in Short Term Borrowings Increase /(Decrease) in share capital 50.00 265.00 Increase /(Decrease) in share Premium Finance Charges (72.39)(242.23)(214.44)(574.89) Net Cash Flow from Financing Activities 136.09 (280.07)322.27 69.32 Actual Payment of Income Tax 0.00 (0.65)D: Net Increase/Decrease in Cash and cash Equivalents 0.00 7.48 0.33 6.40 Opening of Cash & Cash Equivalents 14.14 6.65 16.06 9.66 Closing Balance of Cash & Cash Equivalents 14.14 14.14 16.40 16.06

See accompanying notes to the financial statements As per our report of even date annexed.

Place : Hyderabad Date: 14.11.2024 For and on behalf of Board of Directors

Vanta Bioscience Limited poeile le

LIN

Dopesh Raja Mulaka **Managing Director**

DIN:01176660

Notes to Standalone and consolidated financial statements:

- 1. The above said financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th November, 2024.
- 2. The Statutory Auditors have carried out limited review of the Un Audited Results of the company for the half year ended 30.09.2024.
- 3. The statement are prepared in accordance with the requirements of accounting standards (AS) specified under section 133of Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules 2014.
- 4. As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND—AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND As. Hence it has not adopted IND AS for preparation of Financial Statements.
- 5. Statement of Assets and Liabilities as on 30th September 2024 is enclosed herewith.
- 6. Statement of Cash flow for the period ended 30th September 2024 is enclosed herewith.
- 7. The financial figures for the previous half year/year have been regrouped/reclassified wherever necessary to confirm to current period.
- 8. The Company is engaged in the business of full service preclinical contract Research organization. Hence there is no separate segment reporting required
- 9. The said results are uploaded on the website of the Company www.vantabio.com and on BSE Ltd.

